Skip to main content
. Author manuscript; available in PMC: 2014 Jul 28.
Published in final edited form as: Urol Oncol. 2013 Mar 17;32(1):35.e15–35.e19. doi: 10.1016/j.urolonc.2013.01.009

Table 1.

Patient characteristics (n = 47)

Characteristic
Age
 Median (range) 70 (32–86)
Sex (M:F) 36:11
Location
 Iowa 30
 San Francisco 14
 Minnesota 3
American Society of Anesthesiologists (ASA) score
 Median (range) 3 (1–4)
Stage and grade
 CIS
  CIS 12
  Ta and CIS 7
  T1 and CIS 7
 Ta Only
  Ta Low grade 6
  Ta High grade 4
 T1 Only
  T1 Low grade 0
  T1 High grade 6
 Positive cytology
  High grade 5
Time from initial diagnosis to administration of G/MMC (mo)
 Median (range) 33.5 (0–192)
No. of prior treatments
 Median (range) 2.0 (0–6)
Type of prior treatment
 No prior treatments 7
 BCG naive 10
 1 prior BCG failure 11
 ≥2 or more prior BCG failures 26
Time to failure after BCG (mo)
 Median (range) 5 (3–60)